Harmony Biosciences Holdings (HRMY) stock has moved in different directions over recent periods, with a gain of about 4% in the past week but a decline of roughly 14% year to date.

That mix of a 12.59% 90 day share price return alongside a year to date share price decline of 14.13%, and a 1 year total shareholder return decline of 8.70%, suggests that momentum has picked up recently after a weaker stretch.

If this kind of rebound catches your attention, it can be useful to compare it with other companies by scanning 20 top founder-led companies

With Harmony Biosciences trading at $32.10, an indicated intrinsic discount of 83.62% and a value score of 4, the key question is whether the stock is genuinely undervalued or if the market is already pricing in future growth potential.

Most Popular Narrative: 32.1% Undervalued

With Harmony Biosciences last closing at $32.10 against a narrative fair value of $47.30, the current setup frames a sizeable valuation gap for investors to weigh.

The large and growing patient populations affected by sleep disorders and rare neurodevelopmental conditions, driven by demographic aging and increased recognition/diagnosis, are expanding Harmony's total addressable market, supporting sustained long-term revenue growth for both existing and pipeline products.
Harmony is positioned to capture new sources of revenue and reduce product concentration risk through near-term late-stage pipeline catalysts. These include potential first-to-market launches for ZYN002 in Fragile X syndrome and additional pitolisant formulations (HD and GR), each aimed at high-unmet-need, orphan indications.

Curious what justifies that higher fair value tag? The narrative leans on a specific earnings path, a defined margin profile, and a future multiple that is very different from where the stock trades today.

Result: Fair Value of $47.30 (UNDERVALUED)

However, that upside story can quickly change if legal outcomes accelerate generic Wakix entry, or if late stage assets like ZYN002 or EPX-100 fail to progress as expected.

Next Steps

Given the mixed signals in the share price and valuation, it makes sense to look at the underlying data yourself and pressure test the story before opinions harden. To see what the current upside drivers look like in more detail, take a closer look at the 2 key rewards

Looking for more investment ideas?

If Harmony Biosciences has caught your eye, broaden your watchlist with a few focused stock ideas that match different goals and risk profiles.

• Target potential mispricings by scanning 47 high quality undervalued stocks that combine quality fundamentals with marked gaps between share price and assessed value.
• Prioritise resilience with 63 resilient stocks with low risk scores that show steadier risk scores for investors who prefer fewer surprises.
• Get ahead of the crowd with a screener containing 22 high quality undiscovered gems before wider attention pushes them further onto the market radar.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.